- Home
- PLX vs GLDG Comparison
PLX vs GLDG Comparison
Compare PLX & GLDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- GLDG
- Stock Information
- Founded
- PLX 1993
- GLDG 2009
- Country
- PLX United States
- GLDG Canada
- Employees
- PLX N/A
- GLDG N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- GLDG Precious Metals
- Sector
- PLX Health Care
- GLDG Basic Materials
- Exchange
- PLX Nasdaq
- GLDG Nasdaq
- Market Cap
- PLX 164.2M
- GLDG 159.6M
- IPO Year
- PLX 1998
- GLDG N/A
- Fundamental
- Price
- PLX $2.60
- GLDG $1.29
- Analyst Decision
- PLX Strong Buy
- GLDG Strong Buy
- Analyst Count
- PLX 1
- GLDG 2
- Target Price
- PLX $15.00
- GLDG $3.50
- AVG Volume (30 Days)
- PLX 792.6K
- GLDG 2.1M
- Earning Date
- PLX 11-13-2025
- GLDG 10-14-2025
- Dividend Yield
- PLX N/A
- GLDG N/A
- EPS Growth
- PLX N/A
- GLDG N/A
- EPS
- PLX 0.08
- GLDG N/A
- Revenue
- PLX $61,948,000.00
- GLDG N/A
- Revenue This Year
- PLX $14.53
- GLDG N/A
- Revenue Next Year
- PLX $75.77
- GLDG N/A
- P/E Ratio
- PLX $33.57
- GLDG N/A
- Revenue Growth
- PLX 62.79
- GLDG N/A
- 52 Week Low
- PLX $0.99
- GLDG $0.71
- 52 Week High
- PLX $3.10
- GLDG $1.34
- Technical
- Relative Strength Index (RSI)
- PLX 82.14
- GLDG 67.40
- Support Level
- PLX $1.52
- GLDG $1.18
- Resistance Level
- PLX $2.12
- GLDG $1.29
- Average True Range (ATR)
- PLX 0.12
- GLDG 0.07
- MACD
- PLX 0.05
- GLDG -0.01
- Stochastic Oscillator
- PLX 96.79
- GLDG 84.62
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About GLDG GoldMining Inc.
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; Crucero project, located in Peru; Sao Jorge, Batistao, located in Brazil; Yellowknife Gold Project, located in the Northwest Territories, Canada; and various other projects such as Cachoeira, Yarumalito, Whistler, Surubim, Montes Aureos and Trinta, Rea across different locations. The company has two operating segments, with U.S. GoldMining being one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.